RT Journal Article
SR Electronic
T1 Gasdermin-D activation by SARS-CoV-2 trigger NET and mediate COVID-19 immunopathology
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.24.22269768
DO 10.1101/2022.01.24.22269768
A1 Camila Meirelles Silva
A1 Carlos Wagner S Wanderley
A1 Flavio Protasio Veras
A1 Augusto Veloso Gonçalves
A1 Mikhael Haruo Fernandes Lima
A1 Juliana E. Toller Kawahisa
A1 Giovanni Freitas Gomes
A1 Daniele Carvalho Nascimento
A1 Valter V. Silva Monteiro
A1 Isadora Marques Paiva
A1 Cícero José Luíz Ramos Almeida
A1 Diego Brito Caetité
A1 Juliana da Costa Silva
A1 Maria Isabel Fernandes Lopes
A1 Letícia Pastorelli Bonjorno
A1 Marcela Cavichioli Giannini
A1 Natalia Brasil Amaral
A1 Maíra Nilson Benatti
A1 Luis Eduardo Alves Damasceno
A1 Bruna Manuella Souza Silva
A1 Ayda Henriques Schneider
A1 Icaro Maia Santos Castro
A1 Juan Carlo Santos Silva
A1 Amanda Pereira Vasconcelos
A1 Tiago Tomazini Gonçalves
A1 Sabrina Setembre Batah
A1 Tamara Silva Rodrigues
A1 Victor Ferreira Costa
A1 Marjorie Cornejo Pontelli
A1 Ronaldo B Martins
A1 Timna Varela Martins
A1 Danillo Lucas Alves Espósito
A1 Guilherme Cesar Martelossi Cebinelli
A1 Benedito Antônio Lopes da Fonseca
A1 Luiz Osório Silveira Leiria
A1 Larissa Dias Cunha
A1 Eurico Arruda
A1 Helder I Nakaia
A1 Alexandre Todorovic Fabro
A1 Renê D Oliveira
A1 Dario S Zamboni
A1 Paulo Louzada Junior
A1 Thiago Mattar Cunha
A1 José Carlos Farias Alves Filho
A1 Fernando de Queiroz Cunha
YR 2022
UL http://medrxiv.org/content/early/2022/01/25/2022.01.24.22269768.abstract
AB The release of neutrophil extracellular traps (NETs) is associated with inflammation, coagulopathy, and organ damage found in severe cases of COVID-19. However, the molecular mechanisms underlying the release of NETs in COVID-19 remain unclear. Using a single-cell transcriptome analysis we observed that the expression of GSDMD and inflammasome-related genes were increased in neutrophils from COVID-19 patients. Furthermore, high expression of GSDMD was found associated with NETs structures in the lung tissue of COVID-19 patients. The activation of GSDMD in neutrophils requires live SARS-CoV-2 and occurs after neutrophil infection via ACE2 receptors and serine protease TMPRSS2. In a mouse model of SARS-CoV-2 infection, the treatment with GSDMD inhibitor (disulfiram) reduced NETs release and organ damage. These results demonstrated that GSDMD-dependent NETosis plays a critical role in COVID-19 immunopathology, and suggests that GSDMD inhibitors, can be useful to COVID-19 treatment.In Brief Here, we showed that the activation of the Gasdermin-D (GSDMD) pathway in neutrophils controls NET release during COVID-19. The inhibition of GSDMD with disulfiram, abrogated NET formation reducing lung inflammation and tissue damage. These findings suggest GSDMD as a target for improving the COVID-19 therapy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the Sao Paulo Research Foundation (FAPESP) under grant agreement no. 2013/08216-2 (Center for Research in Inflammatory Diseases) and the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of National Ethics Committee, Brazil (30248420.9.0000.5440) gave ethical approval for this work I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors